Cytori Therapeutics Inc.

The momentum for this stock is not very good. Cytori Therapeutics Inc. is not a good value stock. Cytori Therapeutics Inc. is not a good growth stock. Cytori Therapeutics Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Cytori Therapeutics Inc..
Log in to see more information.
PSTV Fundamental Data by TradingView

News

Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Globe Newswire AUSTIN, Texas, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ( Plus or the Company ), a clinical-stage pharmaceutical company developing targeted radiotherapeutics...\n more…

Buy Rating Affirmed for Plus Therapeutics on Strong Financials and Promising Clinical Trials
Buy Rating Affirmed for Plus Therapeutics on Strong Financials and Promising Clinical Trials

TipRanks Financial Blog Plus Therapeutics (PSTV - Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy...\n more…

PSTV Stock Earnings: Plus Therapeutics Misses EPS, Misses Revenue for Q2 2024
PSTV Stock Earnings: Plus Therapeutics Misses EPS, Misses Revenue for Q2 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nPSTV stock results show that Plus Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second...\n more…

Plus Therapeutics reports Q2 EPS (71c), consensus (53c)
Plus Therapeutics reports Q2 EPS (71c), consensus (53c)

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Globe Newswire Presented Positive Interim ReSPECT-LM Phase 1 Data for Rhenium (186Re) Obisbemeda for Leptomeningeal MetastasesPresented Positive Topline Clinical Trial Results for CNSide diagnostic in the FORESEE...\n more…

Plus Therapeutics to Announce Second Quarter Financial Results and Host Conference Call on August 14, 2024
Plus Therapeutics to Announce Second Quarter Financial Results and Host Conference Call on August 14, 2024

Globe Newswire AUSTIN, Texas, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the Company ), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...\n more…